Ask AI
HRpos HER2neg Breast Cancer

CE

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 20, 2026

Expiration: November 19, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How many people with breast cancer do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A patient presents to your clinic to review her treatment plan (inavolisib + palbociclib + fulvestrant + leuprolide). Based on safety data from the INAVO120 trial, which of the following adverse events are most appropriate to review with the patient and her caregiver?

4.

A patient with germline BRCA-mutated, HR+/HER2- early breast cancer is receiving adjuvant olaparib with endocrine therapy. At follow-up, she reports persistent grade 2 nausea that is affecting daily activities and making it harder to stay on treatment. Which of the following is the best initial management strategy?

5.

Pretest 3: Case Study 


J.C. is a 56-yr-old postmenopausal woman with pT2N1 HR+/HER2- early breast cancer. She completed AC-T and started letrozole + adjuvant abemaciclib therapy 10 days ago.


Her baseline labs are normal.


Today she reports loose stools, 3-4/day above baseline, since Day 3; she is taking fluids but has not added an antidiarrheal yet.


CBC today shows ANC 1.1 × 10⁹/L, although she is afebrile and well appearing.

J.C. is expressing concern about “being on this medication for 2 years if this diarrhea keeps happening.” Beyond antidiarrheal therapy, what pharmacist-led strategy is most likely to prevent treatment interruption?